Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Erdafitinib for treating advanced solid tumours with an FGFR mutation in people aged 6 years and older Erdafitinib (JNJ-42756493; BALVERSA) Solid tumours Haematological Cancer and Lymphomas , Oncology 2021 View  |  Download
Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy Erdafitinib (JNJ-42756493; BALVERSA) Urothelial cancer Urological Cancer 2017 View  |  Download
ERC1671 (Gliovac) for recurrent grade IV glioma Bevacizumab (Avastin; R 435; RG 405; RG 435) , ERC1671 (Gliovac) Glioma Neurological Cancer 2019 View  |  Download
Eptinezumab for prevention of Migraine Eptinezumab (ALD403) Migraine Neurology 2020 View  |  Download
Eplontersen for treating transthyretin amyloid cardiomyopathy Eplontersen (ION-682884;AKCEA TTR-LRx) Transthyretin amyloid cardiomyopathy Cardiovascular System 2024 View  |  Download
Eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy Eplontersen (ION-682884;AKCEA TTR-LRx) Transthyretin-mediated amyloid polyneuropathy Genetic Disorders 2023 View  |  Download
Epcoritamab for treating relapsed or refractory follicular lymphoma Epcoritamab (GEN-3013) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments Epcoritamab (GEN-3013) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy Enzalutamide (Xtandi; MDV3100) Non-metastatic prostate cancer Male Reproductive Cancer 2022 View  |  Download
1 2 74 75 76 77 78 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications